124 related articles for article (PubMed ID: 33812056)
1. Enhancement of target toxin neutralization effect in vivo by PEGylation of multifunctionalized lipid nanoparticles.
Koide H; Suzuki H; Ochiai H; Egami H; Hamashima Y; Oku N; Asai T
Biochem Biophys Res Commun; 2021 May; 555():32-39. PubMed ID: 33812056
[TBL] [Abstract][Full Text] [Related]
2. Design of abiotic polymer ligand-decorated lipid nanoparticles for effective neutralization of target toxins in the blood.
Koide H; Yamauchi I; Hoshino Y; Yasuno G; Okamoto T; Akashi S; Saito K; Oku N; Asai T
Biomater Sci; 2021 Aug; 9(16):5588-5598. PubMed ID: 34241600
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ
Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151
[TBL] [Abstract][Full Text] [Related]
4. pH-labile PEGylation of siRNA-loaded lipid nanoparticle improves active targeting and gene silencing activity in hepatocytes.
Hashiba K; Sato Y; Harashima H
J Control Release; 2017 Sep; 262():239-246. PubMed ID: 28774839
[TBL] [Abstract][Full Text] [Related]
5. PEG shedding-rate-dependent blood clearance of PEGylated lipid nanoparticles in mice: Faster PEG shedding attenuates anti-PEG IgM production.
Suzuki T; Suzuki Y; Hihara T; Kubara K; Kondo K; Hyodo K; Yamazaki K; Ishida T; Ishihara H
Int J Pharm; 2020 Oct; 588():119792. PubMed ID: 32827675
[TBL] [Abstract][Full Text] [Related]
6. Stable Loading and Delivery of Melittin with Lipid-Coated Polymeric Nanoparticles for Effective Tumor Therapy with Negligible Systemic Toxicity.
Ye R; Zheng Y; Chen Y; Wei X; Shi S; Chen Y; Zhu W; Wang A; Yang L; Xu Y; Peng J
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55902-55912. PubMed ID: 34793125
[TBL] [Abstract][Full Text] [Related]
7. Analysis of PEG-lipid anchor length on lipid nanoparticle pharmacokinetics and activity in a mouse model of traumatic brain injury.
Waggoner LE; Miyasaki KF; Kwon EJ
Biomater Sci; 2023 Jun; 11(12):4238-4253. PubMed ID: 36987922
[TBL] [Abstract][Full Text] [Related]
8. PEG-OligoRNA Hybridization of mRNA for Developing Sterically Stable Lipid Nanoparticles toward In Vivo Administration.
Kurimoto S; Yoshinaga N; Igarashi K; Matsumoto Y; Cabral H; Uchida S
Molecules; 2019 Apr; 24(7):. PubMed ID: 30987102
[TBL] [Abstract][Full Text] [Related]
9. Effect of PEGylation on biodistribution and gene silencing of siRNA/lipid nanoparticle complexes.
Bao Y; Jin Y; Chivukula P; Zhang J; Liu Y; Liu J; Clamme JP; Mahato RI; Ng D; Ying W; Wang Y; Yu L
Pharm Res; 2013 Feb; 30(2):342-51. PubMed ID: 22983644
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
[TBL] [Abstract][Full Text] [Related]
11. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
12. Investigating the mechanism of action of DNA-loaded PEGylated lipid nanoparticles.
Digiacomo L; Renzi S; Quagliarini E; Pozzi D; Amenitsch H; Ferri G; Pesce L; De Lorenzi V; Matteoli G; Cardarelli F; Caracciolo G
Nanomedicine; 2023 Sep; 53():102697. PubMed ID: 37507061
[TBL] [Abstract][Full Text] [Related]
13. The presence of PEG-lipids in liposomes does not reduce melittin binding but decreases melittin-induced leakage.
Rex S; Bian J; Silvius JR; Lafleur M
Biochim Biophys Acta; 2002 Feb; 1558(2):211-21. PubMed ID: 11779570
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticles with PEG-variant surface modifications mediate genome editing in the mouse retina.
Gautam M; Jozic A; Su GL; Herrera-Barrera M; Curtis A; Arrizabalaga S; Tschetter W; Ryals RC; Sahay G
Nat Commun; 2023 Oct; 14(1):6468. PubMed ID: 37833442
[TBL] [Abstract][Full Text] [Related]
15. Chelation, formulation, encapsulation, retention, and in vivo biodistribution of hydrophobic nanoparticles labelled with
Hervella P; Dam JH; Thisgaard H; Baun C; Olsen BB; Høilund-Carlsen PF; Needham D
J Control Release; 2018 Dec; 291():11-25. PubMed ID: 30291986
[TBL] [Abstract][Full Text] [Related]
16. Effect of PEG Anchor and Serum on Lipid Nanoparticles: Development of a Nanoparticles Tracking Method.
Berger M; Degey M; Leblond Chain J; Maquoi E; Evrard B; Lechanteur A; Piel G
Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839919
[TBL] [Abstract][Full Text] [Related]
17. RGD-modified lipid disks as drug carriers for tumor targeted drug delivery.
Gao J; Xie C; Zhang M; Wei X; Yan Z; Ren Y; Ying M; Lu W
Nanoscale; 2016 Apr; 8(13):7209-16. PubMed ID: 26972577
[TBL] [Abstract][Full Text] [Related]
18. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery.
Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H
Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909
[TBL] [Abstract][Full Text] [Related]
19. Lipidoid nanoparticles increase ATP uptake into hypoxic brain endothelial cells.
Khare P; Conway JF; S Manickam D
Eur J Pharm Biopharm; 2022 Nov; 180():238-250. PubMed ID: 36265829
[TBL] [Abstract][Full Text] [Related]
20. siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles.
Sakurai Y; Yoshikawa K; Arai K; Kazaoka A; Aoki S; Ito K; Nakai Y; Tange K; Furihata T; Tanaka H; Akita H
J Control Release; 2023 Jan; 353():125-133. PubMed ID: 36414194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
